CommercialCoverageMedium impact
Genetic Testing for Macular Degeneration
Blue Cross & Blue Shield of Mississippi·MS · Ophthalmology, Family Medicine, Internal Medicine·Medical Policy
We identified it
Jun 20, 2026
Summary
BCBS Mississippi has established that genetic testing for macular degeneration is considered investigational and not covered. This policy clarifies that commercial genetic tests like Macula Risk® and 23andMe® testing for age-related macular degeneration will not be reimbursed.
Action Required
Immediately: Billing team should verify that any genetic testing claims for macular degeneration risk assessment are not submitted to BCBS Mississippi as they will be denied. Providers should inform patients that these tests are considered investigational and not covered. Update prior authorization systems to flag macular degeneration genetic testing as non-covered.